Author

A. Varkaris

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:ATAC-seq· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

M. Nouri· 2 shared A. Sowalsky· 1 shared B. Ersoy-Fazlioglu· 1 shared D. J. Einstein· 1 shared E. Corey· 1 shared F. Xie· 1 shared H. Long· 1 shared I. Lee· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

M. Nouri

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Increased chromatin accessibility mediated by nuclear factor I drives transition to androgen receptor splice variant dependence in castration-resistant prostate cancer

L. Poluben, M. Nouri, J. Liang, A. Varkaris, B. Ersoy-Fazlioglu, O. Voznesensky, I. Lee, X. Qiu, L. Cato, J.-H. Seo, M. Freedman, A. Sowalsky, N. Lack, E. Corey, P. Nelson, , S. Balk

This study shows that ARv7 drives AR activity in castration-resistant prostate cancer through increased chromatin accessibility mediated by NFI factors.

bioRxiv · Jan 10, 2024 · PreprintCancer Biology

Polo-like kinase-1 Inhibitors and the Antiandrogen Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling

J. C. Patterson, A. Varkaris, P. J. P. Croucher, M. Ridinger, S. Darlymple, M. Nouri, F. Xie, S. Varmeh, O. Jonas, M. A. Whitman, S. Chen, S. Rashed, L. Makusha, J. Luo, J. T. Isaacs, , M. B. Yaffe

This study shows that combining Plk1 inhibitors with abiraterone synergistically kills cancer cells across tumor types, independent of androgen receptor signaling, through mitotic disruption.

bioRxiv · May 12, 2022 · PreprintCancer Biology